Pirfenidone Tablet, Film Coated
Product Images NDC 42291-492

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Pirfenidone (NDC 42291-492). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avkare, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (491 09)

Label for Pirfenidone Tablets 267 mg film-coated oral tablets by AvKARE. The label indicates prescription-only status with 90 tablets in the package. Dosage storage guidelines and manufacturer information are provided, along with a barcode and QR code for scanning.*

FDA Label Image

2 (491 27)

Pirfenidone Tablets 267 mg film-coated oral tablets packaging label. The label shows a package containing 270 tablets (3 bottles of 90 tablets each) manufactured for AvKARE. The label includes storage instructions, a small image of a beige oval tablet, and an Rx only designation.*

FDA Label Image

3 (492 09)

Pirfenidone Tablets 801 mg film-coated oral tablets packaging label by AvKARE. The label indicates a bottle containing 30 tablets, with storage instructions and usage details. The label includes the NDC number 42291-492-09 and a barcode on the right side.*

FDA Label Image

Structural Formula (Pirfenidone Tablets 1)

Chemical structure of Pirfenidone showing a pyridine ring with a methyl group, a ketone functional group, and a phenyl ring attached to a nitrogen atom.*

FDA Label Image

Figure 1 (Pirfenidone Tablets 2)

A cumulative distribution curve comparing the absolute change in percent predicted forced vital capacity (%FVC) from baseline to week 52 between Pirfenidone and placebo groups. The graph shows the percentage of patients on the vertical axis and absolute change in %FVC on the horizontal axis, highlighting worsening and no decline in lung function outcomes.*

FDA Label Image

Figure 2 (Pirfenidone Tablets 3)

A line graph comparing mean change in FVC (mL) over 52 weeks between Pirfenidone and placebo groups. The x-axis represents time in weeks, and the y-axis shows mean change in FVC (mL). The graph includes two lines: a solid line for Pirfenidone (n=278) and a dashed line for placebo (n=277), illustrating trends over the study period.*

FDA Label Image

Figure 3 (Pirfenidone Tablets 4)

A survival curve graph comparing the percentage of patients alive over time in weeks between Pirfenidone and placebo groups. The graph includes a hazard ratio with confidence interval and a table below showing the number of patients at risk at various time points for each group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.